Ranok Therapeutics Announces U.S. FDA Clearance to Proceed With Its First-in-Human Trial of RNK05047 in Patients With Advanced Solid Tumor Cancers and Lymphomas (CHAMP-1)

--An important milestone for the first protein degrader developed using Ranok’s innovative CHAMP™ technology, with clinical enrollment expected to begin in the first half of 2022 BOSTON & HANGZHOU, China--(BUSINESS WIRE)--Ranok Therapeutics, a biophar...

Full "IntellAsia: Resources" article